Legend Biotech Corporation shares rise 1.04% intraday as Eolas Therapeutics enters new agreement with AstraZeneca.

viernes, 22 de agosto de 2025, 11:11 am ET1 min de lectura
LEGN--
Legend Biotech Corporation rose 1.04% during intraday trading. The stock's movement aligns with the recent news that Eolas Therapeutics entered a new agreement with AstraZeneca, which could potentially impact the biotech sector positively. Additionally, the FTSE 100 hitting a record high and the surge in mining stocks indicate a broader market optimism that may have influenced Legend Biotech's stock performance.

Legend Biotech Corporation shares rise 1.04% intraday as Eolas Therapeutics enters new agreement with AstraZeneca.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios